Ketorolac (Synonyms: RS37619)

Name: Ketorolac
Brand: MedChemExpress
SKU: HY-B0580
Rating: 5.0 (3 reviews)

Cat. No.: HY-B0580 Purity: 99.87%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Ketorolac (RS37619) is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC₅₀s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorolac tromethamine is also a DDX3 inhibitor that can be used for cancer research.

For research use only. We do not sell to patients.

Ketorolac Chemical Structure

CAS No. : 74103-06-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Ketorolac:

3 Publications Citing Use of MCE Ketorolac

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

COX-1

20 nM (IC₅₀)

COX-2

120 nM (IC₅₀)

DDX3

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	13 μM Compound: Toradol	Inhibition of PAK1/COX2 in human A549 cells harboring Ki-RAS mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Inhibition of PAK1/COX2 in human A549 cells harboring Ki-RAS mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 27889630]
A549	IC₅₀	36 μM Compound: Toradol	Inhibition of PAK1 in human A549 cells using myelin basic protein as substrate preincubated for 24 hrs followed by PAK1 immunoprecipation and substrate addition measured after 60 mins by ATP-Glo kinase assay Inhibition of PAK1 in human A549 cells using myelin basic protein as substrate preincubated for 24 hrs followed by PAK1 immunoprecipation and substrate addition measured after 60 mins by ATP-Glo kinase assay	[PMID: 27889630]
B16-F10	IC₅₀	30 μM Compound: Toradol	Cytotoxicity against PAK1-independent mouse B16F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against PAK1-independent mouse B16F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 27889630]

In Vitro

Ketorolac (RS37619) salt (0-30 μM; 48 h) effectively kills the oral cancer cells^[4].
Ketorolac salt (0-5 μM; 48 h) inhibits the expression of DDX3 protein, and induces apoptosis in H357 cells^[4].
Ketorolac salt (0-2.5 μM; 0-16 h) inhibits the proliferation of oral cancer cells^[4].
Ketorolac salt (0-50 μM) directly interacts with DDX3 and inhibits the ATPase activity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:	HOK, SCC4, SCC9 and H357 cells
Concentration:	0-30 μM
Incubation Time:	48 h
Result:	Showed inhibition with IC₅₀s of 2.6, 7.1 and 8.1 μM against H357, SCC4 and SCC9 cells, respectively. And the normal HOK cell line did not show any cell death effect.

Cell Proliferation Assay^[4]

Cell Line:	H357
Concentration:	0.5, 1.0, 1.5, 2.0 and 2.5 μM
Incubation Time:	0, 8 and 16 h
Result:	Inhibited the proliferation.

Western Blot Analysis^[4]

Cell Line:	H357
Concentration:	1, 2.5 and 5 μM
Incubation Time:	48 h
Result:	Significantly reduced DDX3 protein expression levels, but not completely ablated as compared to DMSO treated cells. Up regulated the expression of E-cadherin.

Apoptosis Analysis^[4]

Cell Line:	H357
Concentration:	2.5 and 5 μM
Incubation Time:	48 h
Result:	Induced apoptosis.

In Vivo

Ketorolac (RS37619) (0.4% ketorolac tromethamine ophthalmic solution) shows powerful ocular anti-inflammatory activities in rabbits^[1].
Ketorolac (4 mg/kg/day, p.o.; 2 weeks) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats^[2].
Ketorolac (60 μg; intrathecal injection; once) attenuates the damage caused by spinal cord ischemia in rats^[3].
Ketorolac salt (20 and 30 mg/kg; i.p.; two times in a week for 3 weeks) reduces oral carcinogenesis in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	New Zealand White rabbits (2.0–2.7 kg), LPS endotoxin-induced ocular inflammation^[1]
Dosage:	50 μL ketorolac tromethamine ophthalmic solution 0.4%
Administration:	In eyes, twice, 2 hours and 1 hour before LPS challenge
Result:	Resulted in a nearly complete inhibition (98.7%) of LPS endotoxin-induced increases in FITC (fluorescein isothiocyanate)-dextran in the anterior chamber, and resulted in a nearly complete inhibition (97.5%) of LPS endotoxin-induced increases in aqueous PGE₂ concentrations in the aqueous humor.

Animal Model:	Male Wistar rats (400–450 g), spinal cord ischemia model^[3]
Dosage:	30 and 60 μg
Administration:	Intrathecal injection, 1 h before the ischemia induction for once
Result:	Significantly reduced the motor disturbances and improved the survival rate at 60 μg.

Animal Model:	Significantly reduced the motor disturbances and improved the survival rate at 60 μg.
Dosage:	20 mg/kg and 30 mg/kg
Administration:	IP injection, two times in a week for 3 weeks
Result:	Decreased tumor burden, reduced expression of DDX3 and anti-apoptotic proteins (Bcl-2 and Mcl-1).

Clinical Trial

Molecular Weight

255.27

Formula

C₁₅H₁₃NO₃

CAS No.

74103-06-3

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 200 mg/mL (783.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9174 mL	19.5871 mL	39.1742 mL
5 mM	0.7835 mL	3.9174 mL	7.8348 mL
10 mM	0.3917 mL	1.9587 mL	3.9174 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (285 KB) SDS (394 KB)

COA (255 KB) HNMR (114 KB) RP-HPLC (250 KB) LCMS (233 KB)

Handling Instructions (2659 KB)

References

[1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [Content Brief]

[2]. Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18(6):630-4. [Content Brief]

[3]. Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100(4):1134-9. [Content Brief]

[4]. Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.9174 mL	19.5871 mL	39.1742 mL	97.9355 mL
	5 mM	0.7835 mL	3.9174 mL	7.8348 mL	19.5871 mL
	10 mM	0.3917 mL	1.9587 mL	3.9174 mL	9.7936 mL
	15 mM	0.2612 mL	1.3058 mL	2.6116 mL	6.5290 mL
	20 mM	0.1959 mL	0.9794 mL	1.9587 mL	4.8968 mL
	25 mM	0.1567 mL	0.7835 mL	1.5670 mL	3.9174 mL
	30 mM	0.1306 mL	0.6529 mL	1.3058 mL	3.2645 mL
	40 mM	0.0979 mL	0.4897 mL	0.9794 mL	2.4484 mL
	50 mM	0.0783 mL	0.3917 mL	0.7835 mL	1.9587 mL
	60 mM	0.0653 mL	0.3265 mL	0.6529 mL	1.6323 mL
	80 mM	0.0490 mL	0.2448 mL	0.4897 mL	1.2242 mL
	100 mM	0.0392 mL	0.1959 mL	0.3917 mL	0.9794 mL

Ketorolac Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ketorolac (Synonyms: RS37619)

Customer Review

Other Forms of Ketorolac:

Ketorolac Related Antibodies

3 Publications Citing Use of MCE Ketorolac

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Ketorolac Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ketorolac Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report